The Italian Medicines Agency (AIFA) is making available a Direct Healthcare Professional Communication (DHPC) for Ocrevus (ocrelizumab), used in the treatment of certain forms of multiple sclerosis, to inform healthcare professionals about the risk of drug-induced liver injury.

Patients receiving treatment with Ocrevus should undergo liver function monitoring both before and during treatment and should be informed by their treating physician about the signs and symptoms of possible liver injury.

If liver injury is confirmed, administration of Ocrevus should be discontinued.

The product information will be updated to include information on this adverse reaction, with the frequency category ‘not known’, and on measures to reduce its risk.

Further information is provided in the related document.

Healthcare professionals are reminded of the importance of reporting suspected adverse reactions to ensure continuous monitoring of drug safety and the protection of patient health.